Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

• Dronabinol solution (THC) now available in three countries: Germany, Croatia and Austria
• Cooperation with JACOBY GM enables Cantourage to export THC to Austria for the first time
• Nationwide distribution by JACOBY GM ensures supply to pharmacies and pharmaceutical wholesalers

Berlin, July 5, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01), a leading European company for the production and distribution of cannabis-based medicinal products, has started its cooperation with JACOBY GM in Austria and carried out the first export of dronabinol and the dronabinol solution here. Dronabinol is pure tetra-hydro-cannabidiol, better known as THC. As a result, the solution has now been shipped to the second country in a year and the third country since its launch. Cantourage had first entered the Croatian cannabis pharmaceutical market in April 2023. With this expansion, Cantourage is strengthening its own position in the European market for medicinal cannabis and successfully implementing its internationalization strategy.

Cantourage supplies to the well-known company JACOBY GM Pharma GmbH, a leading Austrian pharmaceutical wholesaler. With around 490 employees, sales of approximately EUR 400 million in 2021 and a total of 7 locations in Austria, JACOBY GM is a strong and established player on the Austrian pharmaceutical market. JACOBY’s business fields include pharmacies, home pharmacies, veterinary medicine, aesthetic medicine, industry and import services.

The introduction of the dronabinol solution is intended to offer new alternatives for dronabinol prescriptions. JACOBY GM’s nationwide distribution ensures that Austrian pharmacies and pharmaceutical wholesalers can be supplied with the product.

“We are very happy that we were able to gain such an experienced and extremely well-established partner as JACOBY GM for the nationwide market entry with dronabinol and the dronabinol solution in Austria,” said Sebastian Blöte, European Sales Director of Cantourage and added: “Our goal is to overturn the currently still existing dronabinol monopolies in many European countries and be able to offer pharmacies this innovative form of dronabinol by significantly simplifying the production process. We are therefore very happy to be working with JACOBY GM, who shares our ambitious vision.”

About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.

More information: www.cantourage.com

This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors in the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.

Press contact Cantourage:
Frederick Steudemann
M +49 (0)30 4701 350-50
pr@cantourage.com